The company reported a net loss of $10.307 million for the year ended December 31, 2025, compared to $11.623 million in 2024. Brainstorm Cell Therapeutics Inc. was delisted from the Nasdaq Capital Market on July 18, 2025, due to non-compliance with minimum shareholder equity requirements and now trades on the OTCQB Venture Market. The Biologics License Application (BLA) for NurOwn for the treatment of ALS was withdrawn on November 3, 2023, after an FDA Advisory Committee voted 17-1-1 against its effectiveness for mild to moderate ALS. The FDA granted a Special Protocol Assessment (SPA) agreement for the design of a planned Phase 3b registrational trial for NurOwn in ALS in April 2024, and alignment on Chemistry, Manufacturing, and Controls (CMC) aspects was reached in June 2024. Cash and cash equivalents amounted to $29,000 at December 31, 2025, with net cash used in operating activities totaling $6.975 million for the year. The company raised $6.880 million from financing activities in 2025, including sales of common stock under at-the-market (ATM) programs, short-term loans, and warrant exercises. A material weakness in internal control over financial reporting was identified related to the initiation, review, authorization, and execution controls for short-term loans. The company is currently involved in a securities class action lawsuit and four consolidated derivative lawsuits filed by shareholders concerning NurOwn's FDA approval prospects and internal controls. Research and development expenses decreased to $4.175 million in 2025 from $4.651 million in 2024, while general and administrative expenses decreased to $5.778 million from $7.042 million over the same period. The company is actively engaged in research and development to evaluate the potential of NurOwn and MSC-NTF derived Exosomes in various neurodegenerative disorders, neurodegenerative eye disease, and acute respiratory distress syndrome (ARDS).